Related Experiment Videos
Itraconazole for the treatment of onychomycosis
A K Gupta1, P De Doncker, R K Scher
1Department of Medicine, Sunnybrook Health Science Center, Toronto, Canada.
Background:
The broad spectrum of activity of itraconazole in vitro manifests itself clinically with the drug being effective for the treatment of onychomycosis caused by dermatophytes, Candida and some non-dermatophyte molds. The pharmacokinetics of itraconazole in the nail results in drug remaining at therapeutic levels for 6-9 months after completion of therapy.
Methods:
An overview of studies where continuous or pulse itraconazole therapy has been used in the treatment of fingernail and toenail onychomycosis.
Results:
Following continuous therapy at 200 mg/day for 3 months for toenail onychomycosis (n = 1741), the rates of clinical cure, clinical response and mycologic cure were: (meta-average +/- 95% standard error (SE)), 52 +/- 9%, 86 +/- 2%, and 74 +/- 3%, respectively, at follow-up 12 months following start of therapy. In fingernail onychomycosis (n = 211), the duration of therapy was 6 weeks and the corresponding efficacy rates at follow-up, 9 months after start of therapy, were meta-average (+/- S.E.) 82 +/- 5%, 90 +/- 2%, and 86 +/- 3%, respectively. In toenail onychomycosis treated with 3 pulses of therapy (n = 1389), the clinical response, clinical cure and mycologic cure were observed in meta-average (+/- S.E.) 58 +/- 10%, 82 +/- 3%, and 77 +/- 5% patients, respectively, at follow-up 12 months after the start of therapy. In fingernail onychomycosis treated with 2 pulses of therapy (n = 210), at follow-up 9 months after the start of therapy, the corresponding efficacy rates were meta-average (+/- S.E.) 78 +/- 10%, 89 +/- 6%, and 87 +/- 8%, respectively.
Conclusions:
Both the continuous and pulse therapy regimens are safe with few adverse effects. Compared to continuous therapy, the pulse regimen has an improved adverse-effects profile, is more cost-effective, and is preferred by many patients.
Insights
Itraconazole effectively treats onychomycosis (nail fungus) in both continuous and pulse therapy regimens. Pulse therapy offers a better safety profile, cost-effectiveness, and patient preference compared to continuous treatment for nail infections.
Area of Science:
- Mycology
- Dermatology
- Pharmacology
Background:
- Itraconazole exhibits broad-spectrum antifungal activity against dermatophytes, Candida, and non-dermatophyte molds.
- The drug's pharmacokinetic profile allows for sustained therapeutic levels in nail tissues for 6-9 months post-treatment.
- This makes itraconazole a viable option for treating various nail fungal infections.
Purpose of the Study:
- To review studies evaluating continuous and pulse itraconazole therapy for fingernail and toenail onychomycosis.
- To compare the efficacy and safety of different itraconazole dosing regimens.
- To assess patient outcomes and preferences for treatment modalities.
Main Methods:
- Systematic review and meta-analysis of clinical studies.
- Inclusion of studies on continuous and pulse itraconazole therapy for onychomycosis.
- Analysis of clinical cure, clinical response, and mycologic cure rates at various follow-up points.
Main Results:
- Continuous therapy for toenail onychomycosis (3 months) showed clinical cure rates of 52% and mycologic cure rates of 74% at 12 months.
- Pulse therapy for toenail onychomycosis (3 pulses) achieved clinical cure rates of 82% and mycologic cure rates of 77% at 12 months.
- Similar high efficacy rates were observed for fingernail onychomycosis with shorter treatment durations and pulse regimens.
Conclusions:
- Both continuous and pulse itraconazole regimens are safe and effective for onychomycosis.
- Pulse therapy demonstrates an improved adverse-effects profile, enhanced cost-effectiveness, and greater patient acceptance.
- The pulse regimen is recommended as a preferred treatment option for nail fungal infections.